Intuitive Surgical, Inc. (NASDAQ:ISRG) has declined more than 29% over the past 6 months and is now trading close to its 52-week lows. The downward pressure stems from regulatory scrutiny regarding instrument reuse and concerns over Chinese competition.
However, the Street expects the stock to rebound, with ******* ysts' 12-month average price target suggesting more than 42% upside, making Intuitive Surgical, Inc. (NASDAQ:ISRG) one of the Top Large Cap Stocks to Invest In At 52-Week Lows.
Recently, on June 23, BTIG ******* yst Ryan Zimmerman reiterated a Buy rating on the stock with a price target of $574. Earlier on June 12, Bank of America Securities had reiterated a Buy rating on the stock with a price target of $515, down slightly from the previous target of $520. The adjustment reflects a more cautious stance on 2027 estimates across BofA's broader medtech coverage.
BofA noted that its services team has flagged a lower utilization environment, suggesting hospitals and surgical centers are using robotic surgery systems less intensively than previously expected. Moreover, the firm's ******* yst Steed also noted that factoring in inflation as a growing headwind in 2027, with less room for margin expansion across the medtech sector.
Intuitive Surgical Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and Ion endoluminal system.
However, the Street expects the stock to rebound, with ******* ysts' 12-month average price target suggesting more than 42% upside, making Intuitive Surgical, Inc. (NASDAQ:ISRG) one of the Top Large Cap Stocks to Invest In At 52-Week Lows.
Recently, on June 23, BTIG ******* yst Ryan Zimmerman reiterated a Buy rating on the stock with a price target of $574. Earlier on June 12, Bank of America Securities had reiterated a Buy rating on the stock with a price target of $515, down slightly from the previous target of $520. The adjustment reflects a more cautious stance on 2027 estimates across BofA's broader medtech coverage.
BofA noted that its services team has flagged a lower utilization environment, suggesting hospitals and surgical centers are using robotic surgery systems less intensively than previously expected. Moreover, the firm's ******* yst Steed also noted that factoring in inflation as a growing headwind in 2027, with less room for margin expansion across the medtech sector.
Intuitive Surgical Inc. (NASDAQ:ISRG) engages in the development, manufacturing, and marketing of da Vinci surgical systems and Ion endoluminal system.
3 months ago
